Welcome to our dedicated page for ODYSSEY THERAPEUTICS SEC filings (Ticker: ODTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ODYSSEY THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ODYSSEY THERAPEUTICS's regulatory disclosures and financial reporting.
Odyssey Therapeutics furnished a new corporate presentation outlining its immunology and inflammation pipeline and recent clinical data. The deck highlights OD-001, an oral RIPK2 inhibitor, which achieved a 27% clinical remission rate in a 12‑week Phase 2a ulcerative colitis trial in 49 patients, with concordant endoscopic and symptomatic endpoints and a clean safety profile to date. Odyssey also presents OD-002, a small-molecule SLC15A4 inhibitor targeting pathogenic B cells and interferon signaling, and OD-003, a TNFR2 agonist protein designed to expand regulatory T cells in major autoimmune indications. The company reports a cash balance of $464M as of March 31, 2026, pro forma for IPO and private placement, which it believes funds operations into the second half of 2028 while it advances multiple programs toward key Phase 1 and Phase 2 readouts.
Odyssey Therapeutics reported a net loss of $38.3 million for the quarter ended March 31, 2026, broadly in line with the prior year. Collaboration revenue fell to zero from $1.9 million as prior Pfizer and Johnson & Johnson research agreements were completed.
Research and development expense was $32.3 million and general and administrative expense was $7.4 million, reflecting continued investment in its autoimmune and inflammatory disease pipeline. Cash, cash equivalents and marketable securities totaled $175.7 million at quarter end.
After the quarter, Odyssey completed an IPO and concurrent private placement, raising net proceeds of about $288.7 million. Together with existing cash, management believes this will fund operations for at least twelve months from issuance of these financial statements.
Odyssey Therapeutics reported first quarter 2026 results and highlighted key clinical and financing milestones. In a Phase 2a monotherapy trial of OD-001 for moderate to severe ulcerative colitis, 27% of 49 treated patients achieved clinical remission after 12 weeks and 61% achieved clinical response, with OD-001 well tolerated at both doses.
As of March 31, 2026, Odyssey held cash, cash equivalents and marketable securities of $175.7 million, and together with $288.7 million of net proceeds from its initial public offering and concurrent private placement, expects funding to last into the second half of 2028, implying a pro-forma cash position of $464M. The company completed an offering of 15,500,000 shares and a private placement of 1,388,889 shares, with underwriters later purchasing 600,000 additional shares at $18.00 per share.
Research and development expenses were $32.3 million versus $38.8 million a year earlier, general and administrative expenses were $7.4 million versus $8.0 million, and net loss was $38.3 million compared to $38.4 million in the prior-year quarter.
FMR LLC reported beneficial ownership of 4,577,262 shares of Odyssey Therapeutics Inc common stock, representing 10.2% of the class as disclosed on the form. The filing lists sole voting and sole dispositive power over the 4,577,262 shares and names Abigail P. Johnson in related disclosures.
Odyssey Therapeutics, Inc. Schedule 13G shows that Lightspeed-affiliated entities report beneficial ownership of 3,608,443 shares of Odyssey Therapeutics common stock. The filing states this equals 7.6% of the class based on 47,174,156 shares outstanding as of May 11, 2026.
The report lists shared voting and dispositive power for the Lightspeed entities and is filed jointly by Lightspeed Venture Partners XV-B (Ignite), L.P., Lightspeed General Partner XV-B (Ignite), L.P., and Lightspeed Ultimate General Partner XV-B (Ignite), L.L.C.
SR One-affiliated funds filed a Schedule 13D reporting beneficial ownership of 3,794,883 shares of Odyssey Therapeutics common stock, representing 8.0% of the company. The stake is held across SR One Fund I Aggregator, SR One Co-Invest vehicles and AMZL, all controlled through SR One Capital Management and ultimately by Dr. Simeon George.
The position arose from Odyssey’s initial public offering of 15,500,000 shares at $18.00 per share and the automatic conversion of multiple preferred stock series and warrants into common stock immediately before the IPO closing. The filing states the investment is for investment purposes, with no current plans for corporate changes.
The funds have registration rights under an Investors' Rights Agreement, including demand and piggyback rights, and are subject to a 180-day lock-up from May 7, 2026 that restricts sales, hedging and registration demands during that period.
TPG-affiliated investors have disclosed a significant new stake in Odyssey Therapeutics, Inc. Funds managed through TPG GP A, LLC now beneficially own 3,690,146 shares of Odyssey common stock, representing about 7.8% of the 47,174,156 shares outstanding as of the IPO closing.
The position includes 1,388,889 shares that TPG LSI Rise Orazio II, L.P. bought directly from Odyssey for $25,000,002 in a concurrent private placement at $18.00 per share, matching the initial public offering price. An Investors' Rights Agreement grants registration rights for resale of these shares, and the filing notes TPG may later consider actions involving Odyssey's operations, capital structure or additional share transactions.
Odyssey Therapeutics, Inc. insider Jolie Siegel reported existing derivative holdings on a Form 3. The filing shows a stock option to buy common stock with an exercise price of $5.15 per share for 78,958 underlying shares, expiring on March 11, 2036. According to the vesting terms, 25% of this option will vest on January 12, 2027, with the rest vesting in 36 equal monthly installments, contingent on continued service.